View clinical trials related to Osteoporosis, Postmenopausal.
Filter by:This study is to evaluate and compare the effects of Alendronate and Risedronate to treat women with postmenopausal osteoporosis. The primary hypothesis for this study is that in postmenopausal women with osteoporosis, treatment with oral alendronate 70 mg once weekly will produce a mean percent increase from baseline in hip trochanter bone mineral density (BMD) at 12 and 24 months which is greater than that observed with oral risedronate 35 mg once weekly.
This study will determine whether treatment with AMG 162 can prevent lumbar spine bone loss in both early and late postmenopausal women with osteopenia, and to further test the safety and tolerability of AMG 162 in this population.
This study will evaluate the effectiveness and safety of denosumab in treating women with Postmenopausal Osteoporosis.
The purpose of this trial is to study: - Effects of arzoxifene on bone fractures and bone mass. - Effects of arzoxifene on getting breast cancer. - Effects of arzoxifene on certain types of cardiovascular events, such as heart attack and stroke. - Effects of arzoxifene that changes the amount of certain substances in the blood that are related to osteoporosis and cardiovascular health. - Effects of arzoxifene on the uterus. - The safety of arzoxifene and any side effects.
Parathyroid hormone (PTH) increases bone formation and thereby improves bone density and bone strength in postmenopausal women with osteoporosis. However, prolonged PTH treatment increases bone formation less and less over time. This study will test whether increasing the daily dose of PTH sustains its ability to improve bone formation, and optional sub-studies will test several potential reasons why PTH's effects on bone formation decline over time.
The purposes of this study are to determine: - The effects of arzoxifene on bone mineral density (bone mass) at the spine and hip in postmenopausal women. - The effects of arzoxifene on the uterus (womb) in postmenopausal women. - The effects of arzoxifene on blood tests that measure changes in bone rebuilding in postmenopausal women with low bone density. - The effects of arzoxifene on blood lipids (fats) and other blood markers of heart disease risk. - The safety of arzoxifene and any side effects that might be associated with its use.
This 2 arm study will assess the long-term efficacy and safety of oral treatment with 100mg or 150mg Bonviva in women with post-menopausal osteoporosis who have previously completed Bonviva study BM16549 (MOBILE study). Patients will receive Bonviva either 100mg po monthly, or 150mg po monthly. Patients will also receive daily supplementation with vitamin D and calcium. The anticipated time of study treatment is 2+ years, and the target sample size is 500+ individuals.
Effects of Teriparatide in Postmenopausal Women Previously Treated with Alendronate or Raloxifene.
Osteoporosis is an important public health problem. Osteoporosis can cause serious health complications and death and leads to increased medical costs. The purpose of this study is to identify an effective method of educating patients and health care professionals about the diagnosis and treatment of osteoporosis.
This study will assess the efficacy and safety of intravenous administration of Bonviva regimens in women with post-menopausal osteoporosis, compared to oral daily administration. Patients will also receive daily supplementation with vitamin D and calcium. The anticipated time of study treatment is 2+ years, and the target sample size is 500+ individuals.